Clinical significance of soluble CD26 in malignant pleural mesothelioma

Nobukazu Fujimoto, Kei Ohnuma, Keisuke Aoe, Osamu Hosono, Taketo Yamada, Takumi Kishimoto, Chikao Morimoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

There is no established single diagnostic marker for malignant pleural mesothelioma (MPM). CD26 is a 110 kDa, multifunctional, membrane-bound glycoprotein that has dipeptidyl peptidase IV (DPPIV) enzyme activity. The aim of this study was to evaluate the clinical significance of soluble CD26 (sCD26) in patients with MPM. The study included 80 MPM patients, 79 subjects with past asbestos exposure (SPE), and 134 patients with other benign pleural diseases (OPD) that were included as a control group. sCD26 levels and DPPIV activity in serum and/or pleural fluid were determined using an ELISA kit. Serum sCD26 levels and DPPIV enzyme activity in patients with MPM were significantly decreased compared with those in the SPE group (P=0.000). The level of serum sCD26 was significantly decreased in patients with advanced stages of MPM compared with those with earlier stages (P=0.047). The median OS of patients with MPM who had higher DPPIV enzyme activity was significantly longer than that of those with lower DPPIV enzyme activity (P=0.032). The sCD26 levels in the pleural fluid of MPM patients with an epithelioid subtype were significantly increased compared with the OPD cohort (P=0.012). Moreover, DPPIV enzyme activity in the pleural fluid of patients with MPM with an epithelioid subtype were significantly increased compared with those in the OPD cohort (P=0.009). Patients with MPM who had lower specific DPPIV activity, determined as DPPIV/sCD26, showed significantly prolonged survival compared with those with higher specific DPPIV activity (P=0.028). Serum sCD26 and DPPIV enzyme activity appear to be useful biomarkers for differentiating patients with MPM from SPE. The sCD26 levels or DPPIV enzyme activity in pleural fluid appear to be biomarkers in patients with an epithelioid subtype of MPM. DPPIV activity in serum or pleural fluid appears to be predictive for the prognosis of patients with MPM.

Original languageEnglish
Article numbere115647
JournalPLoS One
Volume9
Issue number12
DOIs
Publication statusPublished - 2014 Dec 19

Fingerprint

mesothelioma
Dipeptidyl Peptidase 4
Enzyme activity
enzyme activity
Pleural Diseases
Enzymes
Fluids
Serum
Biomarkers
Malignant Mesothelioma
dipeptidyl-peptidase IV
biomarkers
asbestos
Asbestos
Membrane Glycoproteins
prognosis
glycoproteins
Glycoproteins

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Fujimoto, N., Ohnuma, K., Aoe, K., Hosono, O., Yamada, T., Kishimoto, T., & Morimoto, C. (2014). Clinical significance of soluble CD26 in malignant pleural mesothelioma. PLoS One, 9(12), [e115647]. https://doi.org/10.1371/journal.pone.0115647

Clinical significance of soluble CD26 in malignant pleural mesothelioma. / Fujimoto, Nobukazu; Ohnuma, Kei; Aoe, Keisuke; Hosono, Osamu; Yamada, Taketo; Kishimoto, Takumi; Morimoto, Chikao.

In: PLoS One, Vol. 9, No. 12, e115647, 19.12.2014.

Research output: Contribution to journalArticle

Fujimoto, N, Ohnuma, K, Aoe, K, Hosono, O, Yamada, T, Kishimoto, T & Morimoto, C 2014, 'Clinical significance of soluble CD26 in malignant pleural mesothelioma', PLoS One, vol. 9, no. 12, e115647. https://doi.org/10.1371/journal.pone.0115647
Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T et al. Clinical significance of soluble CD26 in malignant pleural mesothelioma. PLoS One. 2014 Dec 19;9(12). e115647. https://doi.org/10.1371/journal.pone.0115647
Fujimoto, Nobukazu ; Ohnuma, Kei ; Aoe, Keisuke ; Hosono, Osamu ; Yamada, Taketo ; Kishimoto, Takumi ; Morimoto, Chikao. / Clinical significance of soluble CD26 in malignant pleural mesothelioma. In: PLoS One. 2014 ; Vol. 9, No. 12.
@article{162774d1419a48c5ae2d50e2ccda8616,
title = "Clinical significance of soluble CD26 in malignant pleural mesothelioma",
abstract = "There is no established single diagnostic marker for malignant pleural mesothelioma (MPM). CD26 is a 110 kDa, multifunctional, membrane-bound glycoprotein that has dipeptidyl peptidase IV (DPPIV) enzyme activity. The aim of this study was to evaluate the clinical significance of soluble CD26 (sCD26) in patients with MPM. The study included 80 MPM patients, 79 subjects with past asbestos exposure (SPE), and 134 patients with other benign pleural diseases (OPD) that were included as a control group. sCD26 levels and DPPIV activity in serum and/or pleural fluid were determined using an ELISA kit. Serum sCD26 levels and DPPIV enzyme activity in patients with MPM were significantly decreased compared with those in the SPE group (P=0.000). The level of serum sCD26 was significantly decreased in patients with advanced stages of MPM compared with those with earlier stages (P=0.047). The median OS of patients with MPM who had higher DPPIV enzyme activity was significantly longer than that of those with lower DPPIV enzyme activity (P=0.032). The sCD26 levels in the pleural fluid of MPM patients with an epithelioid subtype were significantly increased compared with the OPD cohort (P=0.012). Moreover, DPPIV enzyme activity in the pleural fluid of patients with MPM with an epithelioid subtype were significantly increased compared with those in the OPD cohort (P=0.009). Patients with MPM who had lower specific DPPIV activity, determined as DPPIV/sCD26, showed significantly prolonged survival compared with those with higher specific DPPIV activity (P=0.028). Serum sCD26 and DPPIV enzyme activity appear to be useful biomarkers for differentiating patients with MPM from SPE. The sCD26 levels or DPPIV enzyme activity in pleural fluid appear to be biomarkers in patients with an epithelioid subtype of MPM. DPPIV activity in serum or pleural fluid appears to be predictive for the prognosis of patients with MPM.",
author = "Nobukazu Fujimoto and Kei Ohnuma and Keisuke Aoe and Osamu Hosono and Taketo Yamada and Takumi Kishimoto and Chikao Morimoto",
year = "2014",
month = "12",
day = "19",
doi = "10.1371/journal.pone.0115647",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Clinical significance of soluble CD26 in malignant pleural mesothelioma

AU - Fujimoto, Nobukazu

AU - Ohnuma, Kei

AU - Aoe, Keisuke

AU - Hosono, Osamu

AU - Yamada, Taketo

AU - Kishimoto, Takumi

AU - Morimoto, Chikao

PY - 2014/12/19

Y1 - 2014/12/19

N2 - There is no established single diagnostic marker for malignant pleural mesothelioma (MPM). CD26 is a 110 kDa, multifunctional, membrane-bound glycoprotein that has dipeptidyl peptidase IV (DPPIV) enzyme activity. The aim of this study was to evaluate the clinical significance of soluble CD26 (sCD26) in patients with MPM. The study included 80 MPM patients, 79 subjects with past asbestos exposure (SPE), and 134 patients with other benign pleural diseases (OPD) that were included as a control group. sCD26 levels and DPPIV activity in serum and/or pleural fluid were determined using an ELISA kit. Serum sCD26 levels and DPPIV enzyme activity in patients with MPM were significantly decreased compared with those in the SPE group (P=0.000). The level of serum sCD26 was significantly decreased in patients with advanced stages of MPM compared with those with earlier stages (P=0.047). The median OS of patients with MPM who had higher DPPIV enzyme activity was significantly longer than that of those with lower DPPIV enzyme activity (P=0.032). The sCD26 levels in the pleural fluid of MPM patients with an epithelioid subtype were significantly increased compared with the OPD cohort (P=0.012). Moreover, DPPIV enzyme activity in the pleural fluid of patients with MPM with an epithelioid subtype were significantly increased compared with those in the OPD cohort (P=0.009). Patients with MPM who had lower specific DPPIV activity, determined as DPPIV/sCD26, showed significantly prolonged survival compared with those with higher specific DPPIV activity (P=0.028). Serum sCD26 and DPPIV enzyme activity appear to be useful biomarkers for differentiating patients with MPM from SPE. The sCD26 levels or DPPIV enzyme activity in pleural fluid appear to be biomarkers in patients with an epithelioid subtype of MPM. DPPIV activity in serum or pleural fluid appears to be predictive for the prognosis of patients with MPM.

AB - There is no established single diagnostic marker for malignant pleural mesothelioma (MPM). CD26 is a 110 kDa, multifunctional, membrane-bound glycoprotein that has dipeptidyl peptidase IV (DPPIV) enzyme activity. The aim of this study was to evaluate the clinical significance of soluble CD26 (sCD26) in patients with MPM. The study included 80 MPM patients, 79 subjects with past asbestos exposure (SPE), and 134 patients with other benign pleural diseases (OPD) that were included as a control group. sCD26 levels and DPPIV activity in serum and/or pleural fluid were determined using an ELISA kit. Serum sCD26 levels and DPPIV enzyme activity in patients with MPM were significantly decreased compared with those in the SPE group (P=0.000). The level of serum sCD26 was significantly decreased in patients with advanced stages of MPM compared with those with earlier stages (P=0.047). The median OS of patients with MPM who had higher DPPIV enzyme activity was significantly longer than that of those with lower DPPIV enzyme activity (P=0.032). The sCD26 levels in the pleural fluid of MPM patients with an epithelioid subtype were significantly increased compared with the OPD cohort (P=0.012). Moreover, DPPIV enzyme activity in the pleural fluid of patients with MPM with an epithelioid subtype were significantly increased compared with those in the OPD cohort (P=0.009). Patients with MPM who had lower specific DPPIV activity, determined as DPPIV/sCD26, showed significantly prolonged survival compared with those with higher specific DPPIV activity (P=0.028). Serum sCD26 and DPPIV enzyme activity appear to be useful biomarkers for differentiating patients with MPM from SPE. The sCD26 levels or DPPIV enzyme activity in pleural fluid appear to be biomarkers in patients with an epithelioid subtype of MPM. DPPIV activity in serum or pleural fluid appears to be predictive for the prognosis of patients with MPM.

UR - http://www.scopus.com/inward/record.url?scp=84919687999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919687999&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0115647

DO - 10.1371/journal.pone.0115647

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e115647

ER -